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Systemic in vivo delivery of siRNA to tumours
using combination of polyethyleneimine and
transferrin–polyethyleneimine conjugates†‡
Anna M. Grabowska,*a Ralf Kircheis,b Rajendra Kumari,c Philip Clarke,a
Andrew McKenzie,c Jaime Hughes,a Cerys Mayne,a Arpan Desai,d Luana Sasso,d
Susan A. Watsona and Cameron Alexander*d
Materials for delivery of oligonucleotides need to be simple to produce yet eﬀective in vivo to be con-
sidered for clinical applications. Formulations of biomaterials based on combinations of existing demon-
strated polymeric gene carriers with targeted derivatives are potential candidates for rapid translation but
have not been fully explored for siRNA applications. Here we investigated formulations based on deriva-
tised PEI for delivery of siRNA to gastrointestinal cancer cells. siRNA was complexed with linear PEI alone
or with a mixture of linear PEI and transferrin-conjugated branched PEI (TfPEI), and knockdown of repor-
ter genes was investigated. Overall, the in vitro use of complexes containing TfPEI resulted in up to 93%
knockdown at 72 h post-transfection. Sustained knockdown was also achieved in a bioluminescent xeno-
graft model. When complexes were delivered intratumorally, a 43% reduction in luminescence was
achieved in the treated group compared with the control group 48 h after treatment. For systemic adminis-
tration, only the intraperitoneal route, and not the intravenous route was eﬀective, with 49% knockdown
achieved at 72 h and sustained up to 144 h (44%) after a single administration of TfPEI-complexed siRNA.
No toxicity or induction of the interferon response was observed. These ﬁndings demonstrate that simple
formulations of transferrin-conjugated PEI with a ‘parent’ polymer such as linear PEI have potential as a
method for therapeutic delivery of siRNAwhen administered either intratumorally or systemically.
Introduction
Small interfering RNAs (siRNAs) are a powerful tool for down-
regulation of gene expression in mammalian cells.1 Oligo-
nucleotides of this type can be designed for selective targeting of
specific mRNAs, leading to their cleavage and degradation, by
the RNA-induced silencing complex (RISC). Cellular recycling
of the RISC enables targeting of further mRNAs, making the
overall gene silencing process highly eﬃcient. These factors,
together with the high sequence specificity of siRNAs, means
they have potential as therapeutics,2 and in particular, as anti-
cancer agents for downregulation of oncogenes.3
Whilst in vitro delivery of siRNA can be readily achieved,
in vivo delivery has proved more diﬃcult.4 For treatment of
cancer, systemic delivery of siRNA is required to target distant
metastases as well as primary tumours but potential losses via
the kidney and liver or through degradation must be avoided.
Delivery of uncomplexed siRNA has been achieved through the
use of hydrodynamic injection or attachment of cell-targeting
ligands5,6 but neither provides a complete solution.7 Alterna-
tively, siRNAs can be complexed with macromolecules to
protect them from degradative enzymes and increase cellular
uptake,8 but liposomes, for example, activate the innate immune
response and result in toxicity when used systemically.9
The polycation polyethyleneimine (PEI) has been success-
fully used for DNA delivery10,11 and protects siRNA from
serum-associated enzymes. Multiple protonatable amine
groups make PEI eﬃcient in condensing DNA by electrostatic
interactions and separation of nitrogen atoms by a 2 carbon
spacer along the polymer backbone modulates the overall basi-
city. The resulting strong pH buﬀering capacity of linear and
branched PEI has been suggested to enhance endosomal
escape leading to an eﬃcient release of DNA complexes into
the cytoplasm.12 Linear and branched PEI can be synthesised
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and diﬀerent molar mass forms are readily available; linear
and low molecular weight PEI have both been associated with
lower toxicity13,14 and higher eﬃciency of DNA delivery.15,16 In
addition, PEI can be readily functionalised,17,18 as the pres-
ence of primary amines enables standard bioconjugation
chemistries to be used to introduce targeting ligands, self-
assembly inducers and steric shielding groups. These func-
tionalities can enhance circulation times and specific tissue
accumulation in vivo, although there is an inevitable trade-oﬀ
between introduction of a targeting functionality at PEI-amine
groups and loss of binding aﬃnity and buﬀering capacity. In
addition, for a practical pharmaceutical application, there is a
need to make use of expensive or delicate functional aﬃnity
ligands to the minimum level associated with eﬀective target-
ing. Therefore, despite the many potential advantages of PEI
as an oligonucleotide delivery system, the inherent lack of tar-
geting of the unsubstituted parent polycation and the balances
of the introduced functionality, oligonucleotide binding
ability, buﬀering capacity and toxicity have resulted in rather
limited in vivo studies of this polymer as a carrier of
siRNA.19–21
Accordingly, for this study we aimed at evaluating if a
‘minimal-functionalized’ PEI formulation could be made to
enable cancer cell targeting without systemic toxicity, while
retaining strong RNA binding during transit in vivo to main-
tain the therapeutic eﬃcacy. Here we describe the use of a
simple linear PEI co-formulated with a ligand-conjugated
branched PEI for delivery of siRNA to gastrointestinal (GI)
cancer cells in vitro and in vivo. For these studies we utilised
an siRNA sequence for knockdown of luciferase in biolumine-
scent xenograft models, and transferrin as the ligand for cancer
cell targeting. The receptor for transferrin is expressed on pro-
liferating cells22 and has been used for delivery of a range of
therapeutic agents23 to cancer cells, including siRNA.24 In-
corporation of transferrin-conjugated PEI into complexes has also
been shown to improve DNA delivery to tumour cells;25,26 the
mechanism may involve shielding the positive charge on PEI–
DNA complexes in vivo, reducing accumulation in ‘first pass’
organs and enabling them to reach the target tissues including
tumours.27 However, while there have been several in vitro and
in vivo studies of Tf-conjugated PEI alone with siRNA,20,21 the
combination of the linear 22k PEI with branched PEI conju-
gated to Tf had not been evaluated prior to this study. There-
fore, as a first step towards a low cost targeted siRNA
formulation, a mixture of free, and transferrin-conjugated
PEI, was assessed for systemic delivery of siRNA to cancer cells
in vivo.
Methods
Cells
Bioluminescent HCT116 (colorectal, ECACC ref. no. 91091005)
and MGLVA1 (gastric, ascitic variant of MKN 45G28) cells,
stably transfected with firefly luciferase (pORF-LucSh-CpG,
InvivoGen, Toulouse, France) were routinely cultured in
RPMI1640 culture medium (Gibco, Paisley, UK) containing
10% (v/v) heat inactivated foetal bovine serum (FBS, Sigma,
Poole, UK) at 37 °C in 5% CO2 and under humidified
conditions.
siRNA and polycations. For in vitro studies, siRNAs were
purchased from Eurogentec, and for in vivo studies siRNAs
were synthesised by Dharmacon (Lafayette, CO, USA). A
TAMRA-labelled control siRNA29 was used to investigate the
uptake. To investigate siRNA activity, a luciferase siRNA (target
sequence: UCAGAGUGGUGCUGAUGUA) that targets the
pORF-LucSh-CpG-encoded low CpG luciferase was used; a
non-targeting siRNA (SR-CL000-005, sequence not given, Euro-
gentec, Southampton, UK) or one targeting wild-type luci-
ferase, not eﬀective against the low CpG luciferase (sequence:
CGAGUCGUCUUAAUGUAUA) was used. Branched PEI (25 kDa,
Aldrich, Milwaukee, WI, USA) was conjugated to transferrin
and purified as described previously.27 Quantities of protein to
PEI were chosen in accord with these protocols to generate Tf–
PEI25 at a 1 : 1 molar ratio.25 Linear PEI (22 kDa) was obtained
from MBI-Fermentas (St. Leon-Rot, Germany); this form of PEI
was chosen based on the better in vivo properties observed
when PEI mixed with TfPEI was used for DNA delivery
previously.27
Transfection. Transfections were carried out as previously
described.27 5 × 104 cells were transferred to each well of a 24-
well plate the day before transfection in 1 ml of complete
medium (RPMI + 10% fetal calf serum). On the day of trans-
fection, the medium was replaced with 0.3 ml of fresh complete
medium 2 h prior to transfection. A range of N/P ratios
(the ratio between the number of nitrogen groups, N, in the
polymer and the number of phosphate groups, P in the
nucleic acid) was used. Details of the amounts of siRNA and
polymer and the resulting N : P ratio are given in each figure
for each of the individual conditions tested. The amounts used
for the in vivo work are in the Materials and methods section
‘In vivo siRNA delivery’. The appropriate quantity of siRNA was
diluted to 50 μl in Opti-MEM1 (Gibco, Paisley, UK). The
required amount of linear PEI and transferrin-conjugated PEI
(TfPEI), when used, was thawed, vortexed, mixed in the
required ratio, diluted to 50 μl in Opti-MEM1, added to the
nucleic acid and immediately mixed by repeated pipetting. Fol-
lowing incubation at room temperature for 20 min, the com-
plexes were added to cells and cells were returned to the
incubator. Each experiment was repeated on at least two
occasions and the representative data are shown in the figures.
For competitive experiments, free transferrin (Sigma) was
added to the cells immediately prior to addition of the trans-
fection mix in a range of concentrations between 500 and
10 µg ml−1.
Flow cytometry. Cells were removed from the plate with
trypsin/EDTA, washed in fresh medium, resuspended in 4%
formalin and analysed on a Beckman-Coulter XL-MCL flow cyto-
meter; data were analysed using WinMdi (http://facs.scripps.
edu/).
Luciferase reporter assays. Cells were analysed using the
Luciferase assay system (Promega, UK). After washing with
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PBS, cells were lysed in Passive Lysis Buﬀer (Promega), 5 μl was
added to 25 μl of Luciferase Assay Reagent and luminescence
was measured using a MicroLumi XS luminometer (Hartalabs,
USA).
Dynamic light scattering (DLS). Hydrodynamic radii of
polymer–siRNA complexes were determined via scattered light
recorded at a 90° angle to the incident radiation using a Visco-
tek Model 802 Dynamic Light Scattering (DLS) instrument
equipped with an internal laser (825–832 nm) with a
maximum radiation power of 60 mW. Samples were diluted
with filtered, deionized water and at least five measurements
of each sample were taken. Mean and standard deviations were
calculated. Data processing was performed using OmniSize2.
Zeta potential measurement. Zeta (ζ-) potential measure-
ments were derived from electrophoretic mobilities deter-
mined using a Zetasizer Nano ZS (Malvern Instruments Ltd,
UK). Complexes were prepared in 10 mM HEPES buﬀer
adjusted to pH 7.4 and diluted to a concentration of 4 µg ml−1.
Three measurements of each sample with at least 10 repeat
data capture points each were carried out. Mean and standard
deviations of ζ-potentials were calculated.
In vivo siRNA delivery. The study was carried out according
to the UK Coordinating Committee of Cancer (UKCCCR) guide-
lines30 under the UK Home Oﬃce project licence. MGLVA1-
DLuX tumours were established subcutaneously by grafting
into the flank of female MF1-nude mice under anaesthesia
(Hypnorm, Roche/Hypnovel Janssen). The tumour size was
monitored by calliper measurements and imaged under anaes-
thesia using the IVIS®100 imaging system (Caliper Life
Sciences) 15 minutes after administration of a luciferase sub-
strate, D-luciferin (intraperitoneal, 60 mg kg−1 in sterile PBS,
Xenogen, New Jersey, USA). Areas of luminescence were identi-
fied as Regions of Interest (ROIs) and quantified as photons
emitted using Living Image/Igor Pro Software (Caliper Life
Sciences). Mice with tumours of luminescence of greater than
106 were used; bioluminescence is linear over the range used
in this study (Fig. S1†).
Mice were divided into groups, to be injected with a luci-
ferase or control siRNA. For the intratumoral route of injec-
tion, 20 μg of the appropriate siRNA was complexed with a
1 : 4 mixture of TfPEI and PEI as described above but glucose
was added to a final concentration of 3%, in a total volume of
50 μl and the complexed siRNA was injected into two sites
within each tumour. For systemic delivery, single intraperito-
neal injections of 50 µg of siRNA in a final volume of 200 µl
were used. The mice were imaged again for bioluminescence
at timepoints between 24 and 144 h after administration as
indicated; bioluminescence post-treatment was expressed as a
percentage of bioluminescence prior to siRNA injection.
Real-time PCR. RNA extraction, cDNA synthesis and real-
time RT-PCR were performed as described previously,31 using
Sybr Green for detection (Eurogentec). Sequences of the
primers are shown in Table S1.† The relative expression was
calculated using the 2−ΔΔCt method.
Immunohistochemistry. Tumour tissues were formalin-
fixed and paraﬃn-embedded, sectioned, mounted onto poly-
sine coated microscope slides (Thermoscientific, Lough-
borough, UK), dewaxed in xylene, rinsed in sequential alcohols
and rehydrated prior to staining with a mouse monoclonal
antihuman transferrin receptor (AbCam, UK) using the animal
research kit (Dakocytomation, UK) according to the manu-
facturer’s protocol, or rat anti-mouse CD34 antibody (AbCam,
UK) as follows: endogenous peroxidase was blocked with 3%
hydrogen peroxide, antigen retrieval carried out in 10 mM
citric acid at 98 °C for 20 min, blocked using the avidin : biotin
blocking kit (Vector Labs, UK) using a concentration matched
rat IgG2aκ (BD Pharmingen, UK) as a control. Primary label-
ling was visualised with biotinylated goat anti-rat secondary
antibody (BD Pharmingen, UK), followed by a streptavidin
binding complex (Vector Labs Ltd, UK) and diaminobenzidine
tetrahydrochloride chromogen (Dakocytomation, UK). Follow-
ing counterstaining with Mayer’s Haemalum, sections were
coverslipped using DPX. The microvessel density was analysed
by assessment of vessel hotspots across the surface area of the
section at 10× magnification.
Results
Characterisation of complexes
The biological activity of polymer/oligonucleotide polyelectro-
lyte complexes is strongly dependent on the particle size
charge and method of preparation.32 Previous studies on Tf–
PEI complexes with DNA prepared at a Tf : PEI25 molar ratio of
1 : 1 had shown greater transfection eﬃciency for particles of
diameters of <200 nm and positive zeta potentials,27 thus we
utilised Tf : PEI at a 1 : 1 molar ratio for the targeted siRNA
delivery systems. Characterisation of siRNA complexes pre-
pared using mixtures of TfPEI : PEI (1 : 4) and TfPEI : PEI
(1 : 15) at N/P ratios of 8 and 12 was thus carried out using
dynamic light scattering in comparison with PEI complexes
(Table 1). The particle size distributions of PEI complexes were
well-defined with hydrodynamic diameters of 20 or 45 nm
depending on the N : P ratio, based on the number distri-
butions of particles sizes calculated from scattered light inten-
sities. Inspection of correlation functions and calculated
particle sizes from intensity distribution data revealed the
presence of weakly-scattering species in the PEI complexes
with hydrodynamic diameters of <10 nm. Features in this size
range were observed in the absence of siRNA, suggesting that
these signals most likely corresponded to free PEI. Use of
TfPEI : PEI (1 : 4) also resulted in particles in the 20–40 nm dia-
meter range, with essentially all of the particulate content
being of these sizes by number distribution, although the pres-
ence of larger aggregates was apparent in the scattered light
intensity distributions. These variations in the apparent size
were expected for DLS intensity distributions of heterogeneous
particle populations, owing to the sixth power dependency of
scattered light with the particle diameter. There was no detect-
able free polymer–protein conjugate (i.e. TfPEI in the presence
of the polyplexes) and nor were signals corresponding to free
PEI observed. For non-PEI complexes, increased N/P ratios
Biomaterials Science Paper
This journal is © The Royal Society of Chemistry 2015 Biomater. Sci., 2015, 3, 1439–1448 | 1441
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
9 
Se
pt
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 3
0/
11
/2
01
6 
13
:0
3:
54
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
decreased the observed hydrodynamic diameters, implying
better condensation of the oligonucleotide with increased poly-
cation. By contrast, for TfPEI–siRNA complexes at TfPEI : PEI
of 1 : 4, increased N/P ratios resulted in an apparent increase
in the sizes of the most abundant particles, which may have
reflected the increased content of Tf (which has an isoelectric
point of 5.2–5.5 dependent on pH) and the resulting potential
for interparticle association between polycation and negative
domains on the Tf surface. However, the diﬀerences in the
sizes of PEI and TfPEI : PEI (1 : 4) complexes over this N/P
range (i.e. ∼10 nm for both N/P 8 and 12) were considered un-
likely to result in any major changes in biological behaviour,
for example in cell uptake pathways, based on these size vari-
ations alone. The TfPEI : PEI–siRNA complexes at N : P 8 and
N : P 12 were of similar size distributions to the PEI : siRNA
complexes, indicating the likely predominance of the unconju-
gated PEI in the physicochemical behaviour of these species.
Complexes obtained with an N/P ratio of 8 were also charac-
terised in terms of their surface charge (Table 2). PEI com-
plexes exhibited significantly higher mean zeta potentials
(24 mV) compared to TfPEI : PEI (1 : 4) complexes at the same
N/P ratio (zeta potential of 17 mV, p < 0.01). These data were in
accord with those reported previously for Tf–PEI/DNA com-
plexes,33 and suggested a partial shielding of the high surface
charge of PEI in the polyelectrolyte complexes, even at high
N : P ratios, by the attached transferrin (molar mass 80 kDa,
pI = 5.5–5.8, dependent on the Fe content).
Uptake of TfPEI : PEI-conjugated siRNA
Initial in vitro experiments investigated the eﬀects of diﬀerent
amounts of transferrin within the PEI–siRNA complexes on
the uptake of fluorescently-labelled siRNA by HCT116 cells,
chosen as a model cell line well-characterised for expression of
the transferrin receptor, TfR2.34,35 Cells were transfected with
complexes containing 1 : 15 mixtures of TfPEI : PEI, in a range
of N/P ratios, and analysed by flow cytometry at 24 h. Trans-
fection eﬃciencies, assessed as mean fluorescence, for complexes
containing transferrin were similar to those obtained by using
PEI alone. There was an increase in fluorescence at the N/P
ratios of 8 and 16 compared with cells treated with no siRNA
which was significant when 2 μg siRNA was used (Fig. 1a,
Table 2 Zeta potentials of polymer/siRNA complexes
Polycation N/P
Zeta potentiala
(mV)
Conductivity
(mS cm−1)
PEI 8 +24 ± 8 0.26
TfPEI : PEI (1 : 4) 8 +17 ± 11 0.33
TfPEI : PEI (1 : 15) 8 +22 ± 6 0.18
a Recorded in 10 mM HEPES buﬀer adjusted to pH 7.4.
Fig. 1 Uptake of PEI-conjugated siRNA by gastrointestinal cancer cells.
In (a) mean ﬂuorescence is shown 24 h after transfection of HCT116
cells with 1 or 2 μg of TAMRA-labelled siRNA using PEI alone or transfer-
rin-conjugated PEI (TfPEI) mixed with PEI in a ratio of 1 : 15 TfPEI : PEI. *
and ** indicates a signiﬁcant increase (p < 0.05 and p < 0.001 respecti-
vely) in ﬂuorescence compared with cells treated with a transfection
reagent alone (one way ANOVA with the Bonferroni multiple comparison
post-test). In (b) ﬂuorescence microscopy images are shown of cells at
1, 4 or 24 h after transfection with 2 μg TAMRA-labelled siRNA com-
plexed with PEI alone, or TfPEI : PEI (1 : 4 or 1 : 15 mixture, at N/P of 8).
Table 1 Dynamic light scattering by polymer/siRNA complexes
Polycation N/P DH (number distribution ± SD)/nm DH (intensity distribution ± SD)/nm
PEI 8 45 ± 2 (100) 48 ± 2 (6), 204 ± 23 (89), >1 µm (5)
PEI 12 24 ± 1 (100) 22 ± 1 (1), 270 ± 27 (87), >1 µm (12)
TfPEI : PEI (1 : 4) 8 20 ± 1 (100) 20 ± 1 (2), 300 ± 31 (43), 462 ± 88 (27), >1 µm (28)
TfPEI : PEI (1 : 4) 12 38 ± 2 (100) 44 ± 3 (6), 276 ± 40 (88), >1 µm (6)
TfPEI : PEI (1 : 15) 8 23 ± 9 (100) 30 ± 14 (29), 136 ± 60 (68), >1 µm (2)
TfPEI : PEI (1 : 15) 12 21 ± 12 36 ± 9 (63), 274 ± 92 (35), aggregates (2)
Figures in parentheses are the percentage of the sample population.
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p < 0.05 and p < 0.01 for PEI alone and TfPEI : PEI ratio of
1 : 15) and a decrease when the N/P ratio was further increased.
Cells transfected with fluorescent siRNA were also examined
microscopically 1, 4 and 24 h after transfection. In cells trans-
fected using PEI only, at the earlier time-point, a positive
signal was observed only in a proportion of the cells, and in
positive cells, the fluorescence was localised to vesicles which
were widely distributed in the cytoplasm. When TfPEI was
included in the complex, almost all cells were fluorescent at
1 h after transfection. By 4 h, in cells treated with PEI alone,
the fluorescence was clustered into a single area of the cell
outside the nucleus, similar to the pattern in cells treated with
complexes containing TfPEI. By 24 h, the fluorescence signals
were reduced with all treatments, with the strongest reduction
found when PEI alone was used. The representative images are
shown in Fig. 1b. These data together show that despite the
reduced protonatable nitrogen content of PEI following conju-
gation of transferrin, the overall uptake of PEI–siRNA com-
plexes into this cell line was not diminished. In turn, this
implied that the loss of non-specific charge-mediated uptake
through Tf conjugation was at least partially oﬀset by receptor-
mediated endocytosis, even when the TfPEI : PEI ratio was as
low as 1 : 15.
Luciferase knockdown by TfPEI : PEI-conjugated siRNA in gastro-
intestinal cancer cells. We next investigated siRNA-mediated
knockdown in vitro using TfPEI : PEI complexed siRNA. A luci-
ferase siRNA, in complexes containing TfPEI (in a ratio of 1 : 15
or 1 : 4) in a range of N/P ratios, was transfected into HCT116
and MGLVA1 cells (chosen as an established gastric cancer cell
line in vitro and in vivo)36 stably expressing luciferase and luci-
ferase activity measured at d3. The initial experiments demon-
strated that TfPEI : PEI complexes with siRNA were well-tolerated
by both cell lines, with no significant loss in metabolic activity
as measured by MTT assays in HCT-116 cells, and less than 20%
loss in activity in MGLVA-1 cells after 24 h (Fig. S1, ESI†). Knock-
down of approximately 60% was achieved in HCT116 cells at
either TfPEI : PEI ratio, and knockdown was generally main-
tained at d3 (Fig. 2c). In MGLVA1 cells, there was delayed knock-
down, especially at TfPEI : PEI (1 : 15) but knockdown of nearly
90% could be achieved by d3. Overall, maximal, sustained
knockdown was achieved at TfPEI : PEI (1 : 4) using N/P 8–12.
Under these conditions, we observed a small but significant
inhibition of knockdown when free transferrin was added to
the cells immediately before transfection at concentrations of
500 or 100 µg ml−1 suggesting that at least a part of the uptake
is mediated via transferrin receptors (Fig. 2e).
Fig. 2 Knockdown of luciferase activity using TfPEI : PEI siRNA complexes. Percentage knockdown of luciferase activity achieved 24 h (a, b) and
72 h (c, d) after transfection of HCT116 (a, c) or MGLVA1 cells (b, d) using a luciferase-speciﬁc siRNA complexed with transferrin-conjugated PEI
(TfPEI) mixed with PEI in a ratio of 1 : 4 or 1 : 15 TfPEI : PEI relative to a control siRNA. Inhibition of knockdown by free transferrin in MGLVA1 cells
transfected with 2 μg 1 : 4 TfPEI : PEI and 2 µg of siRNA and transfection reagent (e). * indicates concentrations of transferrin that gave signiﬁcant
knockdown relative to ‘no transferrin’ control (p < 0.05).
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In vivo delivery of siRNA using TfPEI–PEI complexes
Intratumoral delivery. Having established that incorporation
of transferrin into the complexes and the concomitant change
in physical properties did not interfere with the siRNA uptake
and knockdown in vitro, the activity of TfPEI : PEI complexed
luciferase siRNA was investigated in an in vivo bioluminescent
MGLVA1 subcutaneous tumour. These tumours showed good
vascularisation and strong staining for transferrin receptors
(Fig. S2†). A dose of 20 μg of luciferase or control siRNA com-
plexed TfPEI : PEI (1 : 4) in an N/P ratio of 8, which had given
sustained knockdown in MGLVA1 cells in vitro, was initially
administered directly into each tumour and bioluminescence
was monitored over 48 h. The representative images of
tumours from both groups are shown in Fig. 3a. Bio-
luminescence at each time-point was expressed as a percentage
of the initial bioluminescence (24 h prior to treatment,
Fig. 3b). Over the whole experiment, taking all timepoints into
consideration, there was a significant diﬀerence between the
bioluminescence in the two groups (p = 0.005, two-way
ANOVA). In the control siRNA group, luminescence increased
over this period (+29%), reflecting continued tumour growth,
while in the luciferase siRNA group, luminescence levelled out
at 24 h post-injection, then decreased by 48 h (32% decrease),
equating to 47.3% lower luminescence in the treated group
compared with the control group at 48 h (p < 0.05, one-way
ANOVA with Bonferroni correction).
Systemic delivery. In a pilot study to investigate the most
appropriate route for systemic delivery, 4 mice were injected
intratumorally, intravenously, or intraperitoneally with com-
plexes containing the luciferase siRNA or intravenously with
the control siRNA, and luminescence was examined at 42 and
68 h after administration of siRNA. Bioluminescence in each
group compared to the control group is illustrated in Fig. 4a.
There was no eﬀect at 42 h post-injection but at 68 h there was
a reduction in bioluminescence in the groups in which siRNA
was administered intratumorally or intraperitoneally, but not in
the group in which the siRNA was administered intravenously.
Next, a larger study was set up in which a complexed luci-
ferase or control siRNA was administered intraperitoneally and
bioluminescence was monitored at 24, 72 and 144 h after
administration. As in the intratumoral study, whilst lumine-
scence in both groups increased due to tumour growth, there
was significant lower bioluminescence in the luciferase siRNA-
treated group compared with the control group, taking into
account all time-points (p = 0.008, two-way ANOVA). At 24 h,
the reduction in bioluminescence (30%) was not significant,
but by 72 h the reduction was significant (49%, p = 0.045, one-
way ANOVA). Knockdown was sustained through to 144 h after
siRNA administration (44% decrease, not sig.) and the lower
bioluminescence in the luciferase siRNA group at the end-
point compared with the control group was also reflected in a
39% reduction in the luciferase mRNA level (data not shown).
General animal conditions were monitored daily and there was
no apparent toxicity associated with delivery of siRNA to the
animals with body weights maintained in both groups. There
was also no significant diﬀerence in the growth of tumours in
the two groups (Fig. S3a†) and no significant induction of the
interferon response at the end-point (Fig. S3b and c†).
Discussion
The data together show that a relatively simple co-formulation
of linear PEI with transferrin-conjugated PEI can be used for
delivery of siRNA to colonic (HCT116) and gastric (MGLVA1)
gastrointestinal cancer cells leading to specific knockdown of
the target gene. The siRNA formulation which gave sustained
knockdown in vitro was also eﬀective in vivo at knocking down
Fig. 3 siRNA knock-down in vivo using the intratumoral route. MGLVA1 cells expressing luciferase were used to establish sub-cutaneous xenografts
in nude mice and imaged 24 h before, and 24 and 48 h after intratumoral injection of a luciferase or control siRNA complexed with TfPEI : PEI in a
ratio of 1 : 4 and an N/P ratio of 8. (a) Representative images of 2 mice treated with a luciferase or control siRNA taken 24 h before, 24 h after or 48 h
after treatment. (b) Percentage change in bioluminescence at 24 and 48 h post-injection. A signiﬁcant reduction in bioluminescence was observed
in the luciferase siRNA-treated group (** indicates p = 0.005, 2-way ANOVA, n = 6) relative to the control siRNA-treated group (n = 7) over the whole
course of the experiment, and a signiﬁcant reduction in the luciferase siRNA compared with the control siRNA-treated group at 48 h (p < 0.05, one-
way ANOVAwith Bonferroni correction) but not at 24 h.
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luciferase activity in MGLVA1 tumours growing subcutaneously
in MF1 nude mice when delivered either intratumorally or sys-
temically via the intraperitoneal route.
The eﬃcacy of the formulation derives from incorporation
of transferrin into PEI/siRNA complexes. Although some inhi-
bition of knockdown by free transferrin was observed,
suggesting that at least some of the uptake is also via specific
receptor binding, most probably the uptake is also due to a
reduction in the polyelectrolyte complex surface charge by the
large (80 kDa) and negatively charged conjugated transferrin,
as shown by the reduced zeta potentials of the Tf–PEI siRNA
complexes compared to those with PEI–siRNA only. Shielding
of the positive charge of PEI in polyelectrolyte complexes has
been hypothesised for PEGylated polymer/DNA complexes
in vivo, through a reduction in plasma protein and red blood
cell binding, leading to prolonged blood circulation and preven-
tion of erythrocyte aggregation.37 However, there are signifi-
cant diﬀerences in physical properties, particularly persistence
length and compaction, of shorter oligonucleotides such as
siRNAs compared to DNA plasmids.24 These in turn mean that
it is not always possible to use polymers optimised for plasmid
DNA therapeutics directly for oligonucleotide delivery.
However, by simple mixing of linear PEI and branched PEI–Tf
conjugates we were able to generate complexes of appropriate
size and charge for siRNA delivery, and demonstrated the par-
ticle uptake in vitro in cancer cell lines. These data indicated
that incorporation of transferrin and the resultant reduction in
the positive charge was not detrimental to the cellular uptake,
and were able to identify TfPEI : PEI and N/P ratios that were
eﬀective in promoting luciferase knockdown. The particles
incorporating TfPEI were similar in size to those using PEI
alone and while zeta potential measurements confirmed that
incorporation of transferrin into the complexes reduced the
positive charge of the particles for complexes prepared at N/P
= 8, addition of transferrin did not generate polyplexes with an
overall negative charge.
In this study we used 22 kDa linear PEI and 25 kDa
branched PEI as similar molecular weight PEIs (<25 kDa) have
previously been shown to be more eﬀective than higher mole-
cular weight forms (∼800 kDa) for delivery of DNA15,38 and
were associated with lower toxicity.13,39 Low molecular weight
linear PEI has been successfully used for intraperitoneal deliv-
ery of siRNA in mice, and it reduced the size of sub-
cutaneously-grown tumours as well as achieving an ∼50%
knockdown in target gene expression. However, in these
studies, gene silencing eﬀects were apparent after 11 days and
multiple injections were required.40 The majority of studies
investigating the use of PEI for siRNA delivery have used the
branched form, either alone38 or conjugated to a peptide e.g.
one targeted to integrin AvB3.41 In a study comparing
branched and linear PEI for siRNA delivery, whilst binding of
linear PEI to siRNA was similar to binding of branched PEI
and the uptake by cells was also observed, the authors did not
achieve knockdown of the target gene.13 This contrasts with
our findings in which we achieved 80–90% knockdown in both
the colonic and gastric cell-lines by day 1 and this was main-
tained up to day 3 of the assays. Diﬀerences in the eﬃcacy of
knockdown is likely due to diﬀerences in the characteristics of
the particles used, including the size, charge and shielding
which are dependent on particle formulation, or character-
istics of the target cells. The formation of smaller complexes
Fig. 4 Systemic delivery of TfPEI-complexed siRNA in vivo. Biolumines-
cent sub-cutaneous MGLVA1 xenografts were established in nude mice.
(a) TfPEI-complexed luciferase siRNA (TfPEI : PEI ratio of 1 : 4 and an N/P
ratio of 8) was administered via intratumoral, intravenous or intraperito-
neal routes (n = 4 mice per group) as a pilot study; a control siRNA was
administered intravenously as control treatment. Bioluminescence at 42
and 68 h post-administration is shown relative to bioluminescence at
24 h pre-administration. Knockdown at 68 h was the greatest when the
intratumoral or intraperitoneal routes of administration were used. (b)
TfPEI-complexed luciferase or control siRNA (TfPEI : PEI ratio of 1 : 4 and
an N/P ratio of 8) was administered via the intraperitoneal routes (n = 7
and 8 respectively) and imaged at 24 h before and 24, 72 and 144 h after
injection. Representative images of 2 mice treated with control or luci-
ferase siRNA taken 24 h before and 72 h after treatment are shown and
the data for all mice are illustrated graphically. A signiﬁcant reduction in
bioluminescence was observed in the luciferase siRNA-treated group
(** indicates p = 0.008, 2-way ANOVA) relative to the control siRNA-
treated group.
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may lead to more eﬃcient uptake due to the increased mobi-
lity of the complexes and increased interaction with negatively
charged cell-surface proteoglycans, but at very high ratios,
release of the nucleic acid into the cytoplasm may be impaired
(i) by a very tight/strong (in extreme cases even non-reversible)
condensation of nucleic acid and/or (ii) due to reduced ability
of small-sized particles to act as a proton sponge.42
The eﬀect of using complexes containing TfPEI has pre-
viously been shown to vary with diﬀerent cell-types.15,25 In this
study, in MGLVA1s there was a greater delay in knockdown
which increased markedly between day 1 and day 3, using a
number of the formulations, but in particular the TfPEI : PEI
ratio of 1 : 15. This may mean that the route of uptake is
diﬀerent in the 2 cell-lines used or that release of the siRNA
from the endosomes may be slower in the MGLVA1s.
Since we had identified the conditions that allowed
eﬃcient and prolonged siRNA delivery in vitro using complexes
incorporating TfPEI, we investigated their function in an
in vivomodel which enabled real-time monitoring of the eﬀect of
siRNA administration. Both intratumoral delivery and systemic
delivery via the peritoneum were eﬀective at reducing luci-
ferase activity in the xenografts whilst, in a pilot study, intrave-
nous delivery was not eﬀective. Biodistribution studies in
which the intravenous delivery routes have been used pre-
viously showed that siRNA complexed with RGD-PEG-PEI com-
plexes accumulates in the liver, and to a lesser extent in the
lung, spleen, heart and kidney,43 while other studies with
modified PEI complexes have shown accumulation in the lung
predominantly,44 thus reducing the eﬀectiveness of delivery.
The intraperitoneal route has previously been successfully
used for delivery of nucleic acids.40,45 In a study using PEI-
complexed siRNA administered intraperitoneally and a sub-
cutaneous ovarian cancer xenograft model, a HER-2 specific
siRNA significantly reduced tumour growth over 14 days com-
pared with a control siRNA.40 Further studies would be needed
to verify the low eﬃciency of delivery by the intravenous route
observed in our small pilot study, to determine the underlying
mechanisms and to investigate whether intravenous delivery of
TfPEI–siRNA complexes can be achieved; however, the current
study provides the proof-of-principle that systemic delivery
using TfPEI–siRNA complexes is feasible.
The downregulation of a luciferase gene as a result of
siRNA administration in this study appears to be specific. The
eﬀects were observed only with an siRNA targeting the luci-
ferase gene expressed by the cells and not when an siRNA,
complexed in an identical manner and targeting a closely
related luciferase gene, was used. The reduction in the bio-
luminescence signal observed in the luciferase siRNA group
compared with the control group at the end-point following
systemic administration (44%) was paralleled by a reduction in
the luciferase mRNA of the same order of magnitude (39%).
Interestingly, as in the in vitro studies, little knockdown was
achieved at 24 h but there was an increase in knockdown at
72 h, which, in the systemic study, was maintained through to
144 h after administration of the siRNA. This may be a result
of delayed release of the siRNA from the particles and sub-
sequent gene knockdown following uptake of the siRNA/poly-
cation particles.
In addition, there were no apparent adverse eﬀects in the
animals as a result of administration of the siRNA complexes;
in the study where siRNA was administered systemically, no
toxicity was observed in the animals over 6 days following
injection and there was no eﬀect on tumour growth, as antici-
pated since the siRNA used targets the luciferase gene and
thus should not aﬀect tumour cell proliferation. The absence
of free PEI in the TfPEI-containing complexes in contrast with
those containing PEI only, as observed from the light scatter-
ing studies, may have contributed to this low toxicity in
addition to the reduced overall charge of the Tf–PEI complexes
compared to PEI/siRNA complexes alone. Lastly, although we
did not use modified siRNAs to prevent induction of the
innate immune response,46,47 we saw only a small non-signifi-
cant increase in the expression of OAS1 and downregulation of
the STAT1 gene. These genes are both involved in the acti-
vation of the innate immune response,48 suggesting that the
siRNAs used do not contain “trigger” sequences49 or that the
formulation used protected them from uptake by immune
cells. However, if delivery was shown to be mediated through
the transferrin receptor rather than through the non-specific
uptake as a result of transferrin-mediated shielding, further
toxicity studies would be required to demonstrate that the
absence of toxicity in this model was not a result of poor
binding of transferrin to the mouse transferrin receptor.
This study provides the proof-of-principle that linear PEI
(22 kDa) co-formulated with transferrin-conjugated branched
PEI (25 kDa) can be used systemically for knockdown of
tumour-expressed genes and therefore has potential as a deliv-
ery agent for treatment of GI cancer. Future studies will investi-
gate the route of uptake, in vivo targeting50 and the relative
eﬃcacy of complexes containing a broader range of polymers.
These include other derivatives of PEI, such as temperature
and/or acid-responsive PEI conjugates,51 alternative cell-
surface ligands41 and new polymer backbones and reporter
groups52 which might further improve the eﬃcacy and control
of siRNA delivery and release in vivo.
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